Rebus (RBSH) S-1 8 Jan 16 IPO registration Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2015
Document Information [Line Items]
Entity Registrant Name	GENSPERA INC
Entity Central Index Key	1,421,204
Entity Filer Category	Smaller Reporting Company
Document Type	S1
Amendment Flag	false
Document Period End Date	Sep. 30, 2015

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 1,240	$ 2,316	$ 3,587
Prepaid expenses	128	197	163
Total current assets	1,368	2,513	3,750
Office equipment, net of accumulated depreciation of $26 and $23	13	12	14
Intangible assets, net of accumulated amortization of $124 and $111	88	101	118
Other assets	3	3	3
Total assets	1,472	2,629	3,885
Current liabilities:
Accounts payable	1,004	989	1,270
Accrued expenses	2,202	1,438	1,250
Convertible notes - stockholder	105	105	105
Total current liabilities	3,311	2,532	2,625
Total liabilities	$ 3,311	$ 2,532	$ 2,625
Commitments and contingencies
Stockholders’ (deficit) equity:
Preferred stock, par value $0.0001 per share; 30,000,000 shares authorized, none issued and outstanding	$ 0	$ 0	$ 0
Common stock, par value $0.0001 per share; 150,000,000 shares authorized, 37,237,356 and 33,181,197 shares issued and outstanding, respectively	4	3	3
Additional paid-in capital	42,285	39,473	33,642
Accumulated deficit	(44,128)	(39,379)	(32,385)
Total stockholders’ (deficit) equity	(1,839)	97	1,260
Total liabilities and stockholders’ (deficit) equity	$ 1,472	$ 2,629	$ 3,885

CONDENSED BALANCE SHEETS _Paren

CONDENSED BALANCE SHEETS [Parenthetical] - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Office equipment, accumulated depreciation (in dollars)	$ 26	$ 23	$ 16
Intangible assets, accumulated amortization (in dollars)	$ 124	$ 111	$ 94
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	30,000,000	30,000,000	30,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000	150,000,000
Common stock, shares issued	37,237,356	33,181,197	27,252,966
Common stock, shares outstanding	37,237,356	33,181,197	27,252,966

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Research and development	$ 459	$ 760	$ 1,885	$ 2,788	$ 3,691	$ 3,711
General and administrative	915	1,035	2,864	2,553	3,307	2,684
Total operating expenses	1,374	1,795	4,749	5,341	6,998	6,395
Loss from operations	(1,374)	(1,795)	(4,749)	(5,341)	(6,998)	(6,395)
Gain on change in fair value of warrant derivative liability					0	1,096
Interest income (expense), net	1	2	0	3	4	(3)
Loss before provision for income taxes	(1,373)	(1,793)	(4,749)	(5,338)	(6,994)	(5,302)
Provision for income taxes	0	0	0	0	0	0
Net loss	$ (1,373)	$ (1,793)	$ (4,749)	$ (5,338)	$ (6,994)	$ (5,302)
Net loss per common share, basic and diluted (in dollars per share)	$ (0.04)	$ (0.05)	$ (0.13)	$ (0.18)	$ (0.23)	$ (0.21)
Weighted average shares outstanding (in shares)	36,856,259	32,693,788	34,569,243	29,589,182	30,413,042	24,816,481

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at Dec. 31, 2012	$ (728)	$ 2	$ 26,353	$ (27,083)
Balance (in shares) at Dec. 31, 2012		22,298,424
Stock-based compensation	1,254	$ 0	1,254	0
Sale of common stock and warrants at $0.70 per share	$ 1,217	$ 0	1,217	0
Sale of common stock and warrants at $0.70 per share (in shares)	776,204	757,794
Sale of common stock and warrants at $1.50 per share (2013) and at $0.80 per share (Private Placement) (2014)	$ 5,000	$ 1	4,999	0
Sale of common stock and warrants at $1.50 per share (2013) and at $0.80 per share (Private Placement) (2014) (in shares)		3,333,356
Reclassification of derivative liability upon exercise of warrants	80	$ 0	80	0
Issuance cost of sales of common stock and warrants	(665)	0	(665)	0
Exercise of warrants	404	$ 0	404	0
Exercise of warrants (in shares)		863,392
Net loss	(5,302)	$ 0	0	(5,302)
Balance at Dec. 31, 2013	1,260	$ 3	33,642	(32,385)
Balance (in shares) at Dec. 31, 2013		27,252,966
Stock-based compensation	1,319	$ 0	1,319	0
Common stock and warrants issued as payment of services and consulting fees	735	$ 0	735	0
Common stock and warrants issued as payment of services and consulting fees (in shares)		798,020
Sale of common stock and warrants at $0.70 per share	3,331	$ 0	3,331	0
Sale of common stock and warrants at $0.70 per share (in shares)		4,163,961
Sale of common stock and warrants at $1.50 per share (2013) and at $0.80 per share (Private Placement) (2014)	773	$ 0	773	0
Sale of common stock and warrants at $1.50 per share (2013) and at $0.80 per share (Private Placement) (2014) (in shares)		966,250
Issuance cost of sales of common stock and warrants	(327)	$ 0	(327)	0
Net loss	(6,994)	0	0	(6,994)
Balance at Dec. 31, 2014	97	$ 3	39,473	(39,379)
Balance (in shares) at Dec. 31, 2014		33,181,197
Stock-based compensation	101	$ 0	101	0
Common stock and warrants issued as payment of services and consulting fees	164	$ 0	164	0
Common stock and warrants issued as payment of services and consulting fees (in shares)		127,712
Sale of common stock and warrants at $0.70 per share	2,515	$ 1	2,514	0
Sale of common stock and warrants at $0.70 per share (in shares)		3,591,278
Issuance cost of sales of common stock and warrants	(254)	$ 0	(254)	0
Exercise of warrants	287	$ 0	287	0
Exercise of warrants (in shares)		337,169
Net loss	(4,749)	$ 0	0	(4,749)
Balance at Sep. 30, 2015	$ (1,839)	$ 4	$ 42,285	$ (44,128)
Balance (in shares) at Sep. 30, 2015		37,237,356

CONDENSED STATEMENT OF STOCKHO6

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) [Parenthetical] - $ / shares	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Shares Issued, Price Per Share	$ 0.70
Private Placement [Member]
Shares Issued, Price Per Share		$ 0.80
Registered Offering [Member]
Shares Issued, Price Per Share		$ 0.80
Warrants 1.773
Shares Issued, Price Per Share			$ 1.773
Warrants 1.50
Shares Issued, Price Per Share			$ 1.50

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	$ (4,749)	$ (5,338)	$ (6,994)	$ (5,302)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	15	18	23	23
Stock-based compensation	265	1,619	2,054	1,254
Change in fair value of derivative liability			0	(1,096)
Decrease (increase) in operating assets:
Prepaid expenses	70	(13)	(34)	(86)
Increase (decrease) in operating liabilities:
Accounts payable and accrued expenses	779	(87)	(93)	500
Cash used in operating activities	(3,620)	(3,801)	(5,044)	(4,707)
Cash flows from investing activities:
Acquisition of office equipment	(4)	(4)	(4)	(8)
Cash used in investing activities	(4)	(4)	(4)	(8)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants sold	2,514	4,104	4,104	6,217
Cost of common stock and warrants sold	(253)	(327)	(327)	(665)
Proceeds from exercise of warrants	287	0	0	405
Cash provided by financing activities	2,548	3,777	3,777	5,957
Net decrease in cash	(1,076)	(28)	(1,271)	1,242
Cash and cash equivalents, beginning of period	2,316	3,587	3,587	2,345
Cash and cash equivalents, end of period	$ 1,240	$ 3,559	$ 2,316	$ 3,587

BACKGROUND

BACKGROUND	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	NOTE 1 – BACKGROUND GenSpera, Inc. (“we”, “us”, “our company”, “our”, “GenSpera” or the “Company”) was formed under the laws of the State of Delaware in November 2003, and has its principal office in San Antonio, Texas. We are an early-stage, pre-revenue, pharmaceutical company focused on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate and other cancers. We plan to develop a series of therapies based on our target-activated prodrug technology platform. Our primary focus at the present time is the clinical development of our lead compound, mipsagargin (formerly referred to as G-202), a novel therapeutic agent with a unique mechanism of action. We have completed a Phase Ia/Ib dose escalation, safety, tolerability and dose refinement study of mipsagargin, in which we treated a total of 44 patients (includes Phase Ia and Ib), including two patients with hepatocellular carcinoma (HCC), or liver cancer, who experienced prolonged stabilization of disease up to eleven months after initiation of treatment. We have completed a Phase II clinical trial of mipsagargin in patients with liver cancer, in which twenty-five patients were treated. In May 2015, we received a final clinical study report. We consider the study outcome achieved positive results, with 63% of treated patients having stable disease at two (2) months, and with a median time to progression of 4.5 months. These results support our plans to continue the development of mipsagargin for patients with liver cancer, as well as proceed with our clinical development strategy in other indications including glioblastoma and prostate cancer trials. Although the data from our completed trials appear promising, the outcome of our ongoing or future trials may ultimately be unsuccessful. We are currently conducting a Phase II clinical trial in glioblastoma (a type of brain cancer), in which eighteen patients have been treated as of November 6, 2015. We have elected to defer opening enrollment for our Phase II prostate clinical trial with mispsagargin until the second quarter of 2016.	NOTE 1 – BACKGROUND GenSpera, Inc. (“we”, “us”, “our company”, “our”, “GenSpera” or the “Company”) was formed under the laws of the State of Delaware in November 2003, and has its principal office in San Antonio, Texas. We are an early-stage, pre-revenue, pharmaceutical company focused on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate and other cancers. We plan to develop a series of therapies based on our target-activated prodrug technology platform. Our primary focus at the present time is the clinical development of our lead compound, mipsagargin (formerly referred to as G-202), a novel therapeutic agent with a unique mechanism of action. We have completed a Phase Ia/Ib dose escalation, safety, tolerability and dose refinement study of mipsagargin, in which we treated a total of 44 patients (includes Phase Ia and Ib), including two patients with hepatocellular carcinoma (HCC), or liver cancer, who experienced prolonged stabilization of disease up to eleven months after initiation of treatment. We are conducting a Phase II clinical trial of mipsagargin in patients with liver cancer, in which twenty-five patients have been treated, and is closed to new patient enrollment. In January 2015, we announced results from our Phase II study in liver cancer patients which indicated that study participants experienced a median time to progression of 4.2 months, nearly twice the time demonstrated in prior studies with placebo or ineffective agents. Thirty-five percent of patients received five or more cycles of treatment with an average time on study of 7.1 months. These results support our plans to continue the development of mipsagargin for patients with liver cancer, as well as proceed with our clinical development strategy in other indications including glioblastoma, prostate cancer and renal cell carcinoma trials. Notwithstanding that the initial and interim data from our trials appear promising, the outcome of our trials is uncertain and our current or future trials may ultimately be unsuccessful. We are currently conducting a Phase II clinical trial in glioblastoma (a type of brain cancer), in which twelve patients have been treated as of March 3, 2015. We also anticipate commencing the enrollment of patients in Phase II clinical trials in patients with prostate and renal cancers during the second quarter of 2015.

MANAGEMENT'S PLANS TO CONTINUE

MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Management Plans to Continue as Going Concern [Abstract]
Management Plans to Continue as Going Concern Disclosure [Text Block]	NOTE 2 – MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN Basis of Presentation We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. We have incurred losses since inception and have an accumulated deficit of $ 44.1 To date, we have generated no sales or revenues, have incurred significant losses and expect to incur significant additional losses as we advance mipsagargin through clinical studies. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. Our cash and cash equivalents balance at September 30, 2015 was $ 1.2 84 2.2 In the event financing is not obtained, we may pursue cost cutting measures as well as explore the sale of selected assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate any of our development programs or clinical trials, these events could have a material adverse effect on: our business, results of operations, and financial condition. These factors raise significant doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Our auditors’ report issued in connection with our a December 31, 2014 financial statements expressed an opinion that our capital resources as of the date of their Audit Report were not sufficient to sustain operations or complete our planned activities for the upcoming year unless we raised additional funds. Accordingly, our current cash level raises substantial doubt about our ability to continue as a going concern past December 2015. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.	Note 2 – Management’s Plans to Continue as a Going Concern Basis of Presentation The opinion of our independent registered accounting firm on our financial statements contains explanatory going concern language. We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. We have incurred losses since inception and have a deficit accumulated of $39.4 million as of December 31, 2014. We anticipate incurring additional losses for the foreseeable future until such time, if ever, that we can generate significant sales from our product candidates currently in development or we enter into cash flow positive business development transactions. To date, we have generated no sales or revenues, have incurred significant losses and expect to incur significant additional losses as we advance mipsagargin through clinical studies. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. Our cash and cash equivalents balance at December 31, 2014 was $2.3 million, representing 88% of our total assets. Based upon our current expected level of operating expenditures, we expect to be able to fund our operations for the next six to nine months. We will require additional cash to fund and continue our operations beyond that point. This period could be shortened if there are any unanticipated increases in planned spending on development programs or other unforeseen events. We anticipate raising additional funds through collaborative arrangements, public or private sales of debt or equity securities, or some combination thereof. There is no assurance that any such collaborative arrangement will be entered into or that financing will be available when needed in order to allow us to continue our operations, or if available, on terms acceptable to us. In the event financing is not obtained, we may pursue cost cutting measures as well as explore the sale of selected assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate any of our development programs or clinical trials, these events could have a material adverse effect on: our business, results of operations, and financial condition. These factors raise significant doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

SUMMARY OF CRITICAL ACCOUNTING

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 3 – SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates. Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, employee compensation and consulting costs and expenses. We incurred research and development expenses of approximately $ 0.5 0.8 1.9 2.8 Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. Nine months ended September 30, 2015 2014 Shares underlying options outstanding 8,921,695 8,425,095 Shares underlying warrants outstanding 26,019,583 19,897,928 Shares underlying convertible notes outstanding 276,936 268,117 35,218,214 28,591,140 Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts. Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3: Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. As of September 30, 2015, the Company has no such assets or liabilities outstanding. We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period. Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life. In August 2014, the FASB issued Accounting Standards Update “ASU” 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This update provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments contained in this update are effective for public and nonpublic entities for annual periods ending after December 15, 2016. We are currently assessing the impact of the adoption of ASU 2014-15, and we have not yet determined the effect of the standard on our ongoing financial reporting. In January 2015, the FASB issued ASU No. 2015-01, Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, simplifying the income statement presentation. The guidance does not change the requirement to disclose items that are unusual in nature and occur infrequently. ASU No. 2015-01 is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, although early adoption is permitted. Exclusive of a material transaction that would qualify for extraordinary item presentation in future periods, we do not expect the adoption of this standard to materially impact our financial statements. In April 2015, the Financial Accounting Standard Board issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2015, and early adoption is permitted. We do not expect the adoption of this standard to materially impact our consolidated financial statements. There are various other recently issued updates, most of which represented technical corrections to the accounting literature or application to specific industries, and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.	NOTE 3 – Summary of Critical Accounting Policies and Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates. Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs. We incurred research and development expenses of $ 3.7 For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts. Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash and cash equivalents were $ 2.3 3.6 1.9 3.1 250,000 We currently outsource all manufacturing of our clinical supplies to single source manufactures. We also have a single source supplier for the active ingredient in our prodrug compounds, including mipsagargin. A change in these suppliers could cause a delay in manufacturing and/or clinical trials, which would adversely affect our Company. Intangible assets consist of licensed technology, patents, and patent applications (see Note 5). The assets associated with licensed technology are recorded at cost and are being amortized on the straight line basis over their estimated useful lives of twelve to seventeen years. Office equipment is stated at cost less accumulated depreciation. Depreciation is calculated on the straight line basis over the estimated useful lives of the assets of three to five years. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to expense. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its office equipment for impairment. Depreciation expense was approximately $ 7,000 6,000 Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. Year Ended December 31, 2014 2013 Shares underlying options outstanding 8,685,095 6,050,623 Shares underlying warrants outstanding 19,897,928 10,216,597 Shares underlying convertible notes outstanding 270,339 261,519 28,853,362 16,528,739 Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts. The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company previously had recorded a warrant derivative liability for warrants with anti-dilution provisions, which all the respective warrants were either exercised or expired as of December 31, 2014 and 2013. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible. We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period. Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life. Certain prior year balances have been reclassified to conform to current year presentation. In August 2014, the FASB issued Accounting Standards Update “ASU” 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This Update provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments in this Update are effective for public and nonpublic entities for annual periods ending after December 15, 2016. We are currently assessing the impact of the adoption of ASU 2014-15, and we have not yet determined the effect of the standard on our ongoing financial reporting. In June 2014, the FASB issued ASU 2014-10 Development Stage Entities (Topic 915). ASU 2014-10 removes all incremental financial reporting requirements from U.S. GAAP for development stage entities. ASU 2014-10 should be applied retrospectively and is effective for fiscal years beginning after December 15, 2014. Early application is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued or made available for issuance. We have decided to adopt ASU 2014-10 early, accordingly all of the past disclosures and presentations for development stage accounting have been eliminated.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Supplemental Cash Flow Information [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION The following table contains additional information for the periods reported (in thousands): Nine months ended September 30, 2015 2014 Non-cash financial activities: Common stock options issued as payment of accrued compensation $ — $ 962 Common stock issued for consulting fees 122 — There was no cash paid for interest and income taxes for the nine months ended September 30, 2015 and 2014.	NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION The following table contains additional information for the periods reported (in thousands). Year Ended December 31, 2014 2013 Non-cash financial activities: Common stock options issued as payment of accrued compensation $ 962 $ 999 Common stock and warrants issued for consulting fees 735 – Derivative liability reclassified to equity upon exercise of warrants – 80 There was no cash paid for interest and income taxes for the years ended December 31, 2014 and 2013.

INTELLECTUAL PROPERTY

INTELLECTUAL PROPERTY	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	NOTE 5 – INTELLECTUAL PROPERTY We solely own or have exclusive licenses to all of our patents and patent applications. Between 2008 and 2011, we entered into license and assignment agreements with Johns Hopkins University (JHU), the University of Copenhagen (UC) and certain co-inventors (Assignee Co-Founders), in which we paid $212,000 in cash and common stock. As a result of these payments and pursuant to the agreements, we acquired worldwide, exclusive, fully paid up rights in know-how, pre-clinical data, development data and certain patent portfolios that relate to, and form the basis of, our technology. Under these agreements, we are not required to make any other future payments, including fees or other reimbursements, milestones, or royalties, to JHU, UC, or the Assignee Co-Founders. Amortization expense recorded during the years ended December 31, 2014 and 2013 was approximately $17,000 for both years. Amortization expense is estimated to be approximately $17,000 for each one of the next five fiscal years.

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 – ACCRUED EXPENSES Accrued expenses consist of the following (in thousands): September 30, 2015 December 31, 2014 Accrued compensation and benefits $ 1,877 $ 1,108 Accrued research and development 145 163 Accrued other 180 167 Total accrued expenses $ 2,202 $ 1,438	NOTE 6 – ACCRUED EXPENSES Accrued expenses consist of the following (in thousands): December 31, 2014 2013 Accrued compensation and benefits $ 1,108 $ 1,040 Accrued research and development 163 82 Accrued other 167 128 Total accrued expenses $ 1,438 $ 1,250

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Notes Payable Disclosure [Abstract]
Notes Payable Disclosure [Text Block]	NOTE 6 – CONVERTIBLE NOTES PAYABLE We previously entered into convertible notes with our chief executive officer pursuant to which we borrowed an aggregate of $ 0.2 0.1 4.2 33,000 30,000 0.50	NOTE 7 – CONVERTIBLE NOTES PAYABLE We have issued convertible notes to our chief executive officer pursuant to which we borrowed an aggregate of $0.2 million, with $0.1 million principal balance outstanding at December 31, 2014. The notes bear an interest rate of 4.2% and matured at various dates through December 6, 2011. Accrued interest at December 31, 2014 and December 31, 2013 was approximately $30,000 and $26,000, respectively. As of December 31, 2014, our chief executive officer has not demanded the payment of the outstanding principal and accrued interest. Accordingly, we consider these amounts due on demand. The notes and accrued interest are convertible, at the option of the holder, into shares of our common stock at a conversion price of $0.50 per share.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 7 – COMMITMENTS AND CONTINGENCIES Legal Matters On July 16, 2015, the U.S. Court of Appeals for the Federal Circuit entered judgment in GenSpera, Inc. v. Annastasiah Mudiwa Mhaka in favor of GenSpera. In a per curiam order without an opinion, the Federal Circuit affirmed the decision of the U.S. District Court for the District of Maryland granting summary judgment in GenSpera's favor in two consolidated cases relating to the inventorship of two patents owned by GenSpera. The district court had issued a declaratory judgment that Dr. Annastasiah Mhaka should not be added as an inventor to the two patents at issue, and had also granted summary judgment with respect to state law tort claims brought by Dr. Mhaka against the company and two of its founders, Dr. John Isaacs and Dr. Sam Denmeade. The U.S. Court of Appeals for the Fourth Circuit previously dismissed another appeal brought by Dr. Mhaka from the same district court judgments.	NOTE 8 – COMMITMENTS AND CONTINGENCIES Operating Leases The Company leases its corporate offices under an operating lease that expires on October 14, 2015 56,000 55,000 2015 $ 45 Thereafter Total minimum lease payments $ 45 Employment Agreements We employ our Chief Executive Officer and Chief Operating Officer pursuant to written employment agreements. The employment agreements contain severance provisions and indemnification clauses. The indemnification agreement provides for the indemnification and defense of the executive officers, in the event of litigation, to the fullest extent permitted by law. Chief Chief Terminated without cause $ 1,789 $ 969 Terminated, change of control without good reason 1,789 — Terminated for cause, death, disability and by executive without good reason 381 325 Legal Matters On March 12, 2012, GenSpera instituted a declaratory judgment action against Annastasiah Mhaka (“Mhaka”) in the United States District Court for the District of Maryland: GenSpera, Inc. v. Mhaka, Civil Action No. MJG-12-772 (D. Md.). In its complaint, GenSpera, as the exclusive licensee of the inventions described and claimed in the U.S. Patent No. 7,468,354 (“the ‘354 patent”) and U.S. Patent No. 7,767,648 (“the ‘648 patent”), sought a declaratory judgment that Mhaka should not be added to either the ‘354 patent or the ‘648 patent as an inventor. On April 2, 2012, Mhaka filed and served her answer and counterclaim, in which she sought to be added as an inventor to the ‘354 patent and the ‘648 patent pursuant to 35 U.S.C. § 256. On November 1, 2012, Mhaka filed a second complaint in Maryland state court, asserting state tort claims against GenSpera and Drs. Samuel Denmeade and John Isaacs. On May 1, 2013, the District Court granted GenSpera’s motion for summary judgment in the original case. Reserving any ruling on the issue of whether Mhaka’s state law tort claims were preempted by federal patent law, the Court denied defendants’ motion to dismiss Mhaka’s complaint in the second case and directed Mhaka to re-file her claims as counterclaims in the original action. On May 14, 2013, Mhaka filed an amended answer and counterclaims in the consolidated action, re-pleading her tort claims as counterclaims. On June 3, 2013, GenSpera (along with Drs. Denmeade and Isaacs) filed a reply to the counterclaims, denying their allegations and raising a number of affirmative defenses. On January 2, 2014, Drs. Isaacs and Denmeade moved for summary judgment on the grounds that Mhaka’s tort claims were barred by the applicable statute of limitations, and GenSpera joined in the motion. On May 6, 2014, GenSpera moved separately for summary judgment, a motion that Drs. Denmeade and Isaacs joined in part. On September 12, 2014, the District Court granted GenSpera’s motion for summary judgment as well as the motion for summary judgment filed by Drs. Denmeade and Isaacs. Judgment in favor of GenSpera, Dr. Isaacs, and Dr. Denmeade was entered concurrently for purposes of both the original case and the second case. On October 10, 2014, Mhaka filed notices of Appeal with the United States Courts of Appeals for the Fourth Circuit and Federal Circuit. On December 11, 2014, GenSpera (along with Drs. Denmeade and Isaacs) filed a motion to dismiss the appeal before the United States Court of Appeals for the Fourth Circuit on the ground that the Court of Appeals for the Federal Circuit possesses exclusive jurisdiction over any appeal from the District Court. On December 29, 2014, Mhaka filed an opposition to the motion to dismiss and moved the Court of Appeals for the Fourth Circuit to stay appellate proceedings pending resolution of the appeal before the United States Court of Appeal for the Federal Circuit. On January 12, 2015, the Appellees filed an opposition to the motion to stay. On March 17, 2015, the Court of Appeals for the Fourth Circuit dismissed Mhaka’s appeal for lack of jurisdiction. In the appellate proceedings before the United States Court of Appeals for the Federal Circuit, Mhaka originally filed her opening brief on December 26, 2014. Mhaka filed a corrected opening brief on January 20, 2015. On February 12, 2015, the Appellees filed their responsive brief, and on March 16, 2015, Mhaka filed a reply brief. Oral argument on the appeal has yet to be scheduled.

CAPITAL STOCK AND STOCKHOLDER'S

CAPITAL STOCK AND STOCKHOLDER'S EQUITY	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 – CAPITAL STOCK AND STOCKHOLDER’S EQUITY Common Stock In September 2015, the board of directors approved amending the Company’s certificate of incorporation to effect a reverse stock split, subject to shareholder approval, of the Company’s issued and outstanding common stock at a ratio of not less than one-for-two (1 for 2), and not more than one-for thirty (1 for 30). Accordingly, the company was given the authority to take the action necessary to obtain shareholder approval at the shareholder meeting scheduled to be held on November 13, 2015. In August 2015, we cancelled and retired an aggregate of 27,288 25,000 In July 2015, we granted an aggregate of 125,000 95 30,000 27 In July 2015, we also offered and sold 3,591,278 0.70 0.80 0.70 During the nine months ended September 30, 2015, 337,169 287,000	NOTE 9 – CAPITAL STOCK AND STOCKHOLDER’S EQUITY Common Stock In December 2014, we issued a total of 424,522 Thapsia garganica 280,000 In October 2014, we issued a total of 20,000 15,000 In August 2014, we issued an aggregate of 25,000 20,000 1.15 189,364 169,000 In February 2014, we entered into an agreement with H.C. Wainwright to serve as our exclusive advisor for a proposed offering of our securities. Pursuant to the placement agent agreement, we agreed to a cash placement fee equal to 8 8 4 4 In February 2014, we entered into an agreement for method development by a contract manufacturer and issued an aggregate of 91,334 127,000 47,800 67,000 During the year ended December 31, 2014, no warrants were exercised into common shares. During the year ended December 31, 2013, 325,670 404,000 537,722 Equity Financing June 2014 Registered Offering On May 23, 2014, our registration statement on Form S-1 (File No. 333-194687) was declared effective by the United States Securities and Exchange Commission. Pursuant to the registration statement, we offered and sold 4,163,961 0.80 3.0 278,000 64,000 50,000 326,817 Each Series A warrant has an exercise price of $ 1.15 0.85 0.85 June 2014 Private Placement In June 2014, we are also offered and sold 966,250 0.80 1.15 August 2013 Offering In August of 2013, we sold an aggregate of $ 5,000,032 3,333,356 1.50 1.75 6 4.99 9.99 In connection with the offering, we also paid commissions equal to 8 400,003 2 100,001 266,668 35,000 a cash fee of 4% of gross proceeds received from the exercise of the warrants, and (ii) additional transaction fees equal to 8% of gross proceeds and 8% warrant coverage for any future investment by one of the investors in the Company for a period of 12 months following the closing of the offering. In connection with the offering, investors received certain registration rights. Pursuant to the registration rights, the Company agreed to file a registration statement with the SEC within 45 days from the closing to register the resale of the common shares and common shares underlying the warrants. The Company also agreed to have the registration statement declared effective within 120 days from the filing date. The Company agreed to keep the registration statement continuously effective until the earlier to occur of (i) the date after which all of the securities to be registered thereunder have been sold, or (ii) the date on which all the securities to be registered thereunder may be sold without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 under the Securities Act of 1933, as amended. We are also obligated to pay the investors, as partial liquidated damages, a fee of 1.5

STOCK OPTIONS

STOCK OPTIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 9 – STOCK OPTIONS Our 2009 Executive Compensation Plan (“2009 Plan”) and our 2007 Equity Compensation Plan (“2007 Plan”) allow for the issuance of up to 6,000,000 12,000,000 Nine months ended September 30, 2015 2014 Research and development $ 28 $ 25 General and administrative 73 249 $ 101 $ 274 Weighted- Weighted-average Aggregate average remaining intrinsic Number of exercise contractual term value (in shares price (in years) thousands) Outstanding at December 31, 2014 8,685,095 $ 1.65 Granted 376,600 $ 0.79 Exercised — — Forfeited (140,000) $ 2.17 Outstanding at September 30, 2015 8,921,695 $ 1.60 3.3 $ — Exercisable at September 30, 2015 8,712,445 $ 1.62 3.3 $ — As of September 30, 2015, there was approximately $ 72,000 During the nine months ended September 30, 2015, we issued options to purchase 159,000 217,600 1,948,902 159,000 391,570 Nine months ended September 30, 2015 2014 Volatility 58.4 % 55.6 % Expected term (years) 3.4 3.3 Risk-free interest rate 1.0 % 0.6 % Dividend yield 0 % 0 %	NOTE 10 – STOCK OPTIONS Deferred Compensation Plan In July of 2011, we adopted Executive Deferred Compensation Plan (the Deferred Plan). The Deferred Plan is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the Code). The Deferred Plan is intended to be an unfunded “top hat” plan which is maintained primarily to provide deferred compensation benefits for a select group of our “management or highly compensated employees” within the meaning of Sections 201, 301, and 401 of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and to therefore be exempt from the provisions of Parts 2, 3, and 4 of Title I of ERISA. The Deferred Plan is intended to help build a supplemental source of savings and retirement income through pre-tax deferrals of eligible compensation, which may include cash, option and stock bonus awards, discretionary cash, option and stock awards and/or any other payments which may be designated by the Deferred Plan administrator, as eligible, for deferral under the Deferred Plan from time to time. As administered, the Deferred Plan is used to defer compensation of stock awards granted under our other equity compensation plans and does not by its terms approve any grants or awards. GenSpera’s Compensation Plans The Company’s 2007 Equity Compensation Plan (2007 Plan) and 2009 Executive Compensation Plan (2009 Plan) (together, the Plans) provide for the awarding of stock grants, nonqualified and incentive stock options, restricted stock units, performance units or other stock-based awards to officers, directors, employees and consultants of the Company. The purpose of the Plans is to advance the interests of GenSpera and our stockholders by attracting, retaining and rewarding persons performing services for us and to motivate such persons to contribute to our growth and profitability. Our Plans are administered by a committee of non-employee directors (the Committee). The Committee determines: who shall be granted awards; the vesting periods; the exercise price; and any other terms deemed appropriate for any award. As of December 31, 2014, our 2009 Plan authorized up to 6,000,000 shares of common stock to be reserved for issuance upon exercise of stock options or other stock-based awards, and the Company has awarded 4,945,874 stock options, and 1,054,126 shares of common stock were available for future grants under the 2009 Plan. All option awards granted under the 2009 Plan are fully vested. Our 2007 Plan authorizes up to 6,000,000 shares of common stock to be reserved for the issuance upon exercise of stock options or other stock-based awards, subject to an annual award limitation of 1,500,000 shares. Under the 2007 Plan, vesting schedules for stock options vary, but generally vest for a period of not more than five years and at a rate of not less than 20% per year. The maximum term of an option granted under the 2007 Plan is ten years. As of December 31, 2014, the Company has awarded 4,174,221 stock options, and 2,090,779 shares of common stock were available for future grants under the 2007 Plan. 2014 2013 Research and development $ 891 $ 483 General and administrative 1,164 771 Total stock-based compensation expense $ 2,055 $ 1,254 Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2012 4,674,628 $ 1.79 Granted 1,515,995 $ 2.02 Exercised – – Forfeited (140,000) $ 2.80 Outstanding at December 31, 2013 6,050,623 $ 1.82 4.0 $ 272 Granted 2,759,472 $ 1.26 Exercised – – Forfeited (125,000) $ 1.50 Outstanding at December 31, 2014 8,685,095 $ 1.65 4.0 $ 46 Exercisable at December 31, 2014 8,559,895 $ 1.66 4.0 $ 46 As of December 31, 2014, there was $43,000 of total unrecognized compensation cost related to non-vested stock options which vest over time, and is expected to be recognized over a weighted-average period of 1.2 years. As of December 31, 2013, there was $0.1 million of total unrecognized compensation cost related to non-vested stock options which vest over time, and is expected to be recognized over a weighted-average period of 0.5 years. During 2014 and 2013, the Company issued options to purchase 2,107,902 and 1,335,972 shares of common stock, respectively, to employees, and non-employee directors under the Plans. The weighted-average fair value of the options granted to employees and non-employee directors during 2014 and 2013 was estimated at $0.48 and $0.84 per share, respectively, on the date of grant. During 2014 and 2013, the Company issued options to purchase 651,570 and 180,023 shares of common stock, respectively, to consultants under the Plan. The per-share weighted-average fair value of the options granted to consultants during 2014 and 2013 was estimated at $0.38 and $0.75, respectively, on the date of grant. Year Ended December 31, 2014 2013 Volatility 55.8 % 58.8 % Expected term (years) 3.5 3.7 Risk-free interest rate 0.7 % 0.6 % Dividend yield None None No options were exercised during the years ended December 31, 2014 and 2013.

WARRANTS

WARRANTS	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 10 – WARRANTS We account for common stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant. Warrants are accounted for as derivative liabilities if the warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of common stock by the Company are at a lower price per share than the then-current warrant exercise price. As of September 30, 2015, there were no outstanding liability-classified warrants. Weighted- Weighted-average Aggregate average remaining intrinsic Number of exercise contractual term value (in shares price (in years) thousands) Outstanding at December 31, 2014 19,897,928 $ 1.54 Granted 7,694,859 $ 0.75 Exercised (337,169) $ 0.70 Forfeited (1,236,035) $ 3.16 Outstanding at September 30, 2015 26,019,583 $ 1.24 2.3 $ — Exercisable at September 30, 2015 26,019,583 $ 1.24 2.3 $ — During the nine 337,169 287,000 Weighted- average Number of exercise shares price Expiration Issued to consultants 1,057,667 $ 1.91 December 2015 through May 2020 Issued pursuant to 2011 financings 1,936,785 $ 3.24 January 2016 through April 2016 Issued pursuant to 2012 financings 296,366 $ 3.00 December 2017 Issued pursuant to 2013 financings 4,376,228 $ 1.97 December 2017 through August 2018 Issued pursuant to 2014 financings 10,882,678 $ 0.82 December 2015 through June 2019 Issued pursuant to 2014 financings 7,469,859 $ 0.75 January 2017 through July 2020 26,019,583 During the nine months ended September 30, 2015, in connection with a private placement, we issued an aggregate of 7,469,859 7,182,556 287,303 0.70 0.80 225,000 0.65 0.30 During the nine months ended September 30, 2014, in connection with a registered offering, we issued an aggregate of 10,736,722 10,409,905 326,817 0.85 1.15 483,125 1.15 3,826,792 4,163,961 0.70 December 31, 2016 During the nine months ended September 30, 2014, we issued warrants to consultants to purchase 248,000 1.15 3.00 0.36 Total stock-based compensation expense of approximately $ 67,000 90,000 Nine months ended September 30, 2015 2014 Volatility 72.7 % 52.0 % Expected term (years) 1.7 2.0 Risk-free interest rate 0.6 % 0.5 % Dividend yield 0 % 0 %	NOTE 11 – WARRANTS AND DERIVATIVE WARRANT LIABILITY We account for common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Common stock warrants are accounted for as derivative liabilities if the stock warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of common stock are at a lower price per share than the then-current warrant exercise price. We classify derivative warrant liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant. Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2012 8,513,984 $ 2.47 Granted 4,376,228 $ 1.97 Exercised (1,325,670) $ 1.06 Forfeited (1,347,945 1.52 Outstanding at December 31, 2013 10,216,597 $ 2.56 2.9 $ 48.0 Granted 11,467,847 $ 0.95 Forfeited (1,786,516) $ 2.85 Outstanding at December 31, 2014 19,897,928 $ 1.61 1.8 $ 8.4 Exercisable at December 31, 2014 19,897,928 $ 1.61 1.8 $ 8.4 During the year ended December 31, 2014, no warrants were exercised into common shares. During the year ended December 31, 2013, 325,670 404,000 1,000,000 537,722 Number of Weighted Expiration Equity–classified warrants Issued to consultants 1,045,759 $ 2.22 May 2015 through August 2019 Issued pursuant to 2010 financings 1,022,943 $ 3.38 January 2015 through May 2015 Issued pursuant to 2011 financings 1,936,785 $ 3.24 January 2016 through April 2016 Issued pursuant to 2012 financings 296,366 $ 3.00 December 2017 Issued pursuant to 2013 financings 4,376,228 $ 1.97 December 2017 through August 2023 Issued pursuant to 2014 financings 11,219,847 $ 0.93 December 2015 through June 2019 19,897,928 Equity-classified Warrants During 2014, the Company issued warrants to consultants to purchase 248,000 0.36 89,000 Volatility 51.1 % Expected term (years) 2.0 Risk-free interest rate 0.5 % Dividend yield None In June 2014, in connection with our registered offering, we issued an aggregate of 10,736,722 10,409,905 326,817 0.85 1.15 483,125 1.15 In 2014, we also issued warrants to consultants to purchase 248,000 0.36 In August 2013, in connection with an offering of our securities, we issued an aggregate of 776,204 686,420 18,410 71,374 3.00 3,600,024 3,333,356 266,668 1.75 In 2013, in connection with multiple closings of the December 2012 offering, the Company issued an aggregate of 776,204 686,420 18,410 71,374 3,600,024 3,333,356 266,668 1.75 Liability-classified Warrants The Company has assessed its outstanding equity-linked financial instruments and has concluded that certain of its common stock purchase warrants are subject to derivative accounting, as a result of certain anti-dilution provisions contained in the warrants. The fair value of these warrants was classified as a liability in the financial statements with the change in fair value during the periods presented recorded in the statement of operations. At December 31, 2013, all outstanding liability-classified warrants were either exercised or had expired. We did not record a gain or loss during the year ended December 31, 2014, as the outstanding liability-classified warrants were either exercised or had expired. We recorded a gain of $ 1.1 80,000 242,000

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 12 INCOME TAXES The Company had, subject to limitation, $ 27.8 which will expire at various dates beginning in 2015 through 2025 443,000 which will expire from 2028 through 2035 100 2.4 1.8 2014 2013 Deferred tax assets: Net operating loss carryover $ 9,466 $ 7,590 Stock-based compensation 3,372 2,888 Tax credits 443 398 Total deferred tax assets 13,281 10,876 Less: valuation allowance (13,281) (10,876) Net deferred tax assets $ – $ – 34 2014 2013 Statutory federal income tax rate -34.0 % -34.0 % Permanent differences 0.0 % -7.0 % Adjustment for R&D Credit 0.2 % 0.2 % Valuation allowance 33.8 % 40.8 % Effective income tax rate – % – % The Company’s tax returns for the previous three years remain open for audit by the respective tax jurisdictions.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 11 – SUBSEQUENT EVENTS In October 2015, the board of directors approved amending the conversion price of the convertible notes entered into with our chief executive officer from a price of $ 0.50 0.40 262,500 In November 2015, we issued a warrant to a consultant to purchase 75,000 0.35 0.15	NOTE 13 – SUBSEQUENT EVENTS In February and March 2015, certain holders of the Company’s Series B warrants exercised their warrants to purchase an aggregate of 337,169 0.85 0.3 In March 2015, we entered into a consulting agreement and issued an aggregate of 30,000

SUMMARY OF CRITICAL ACCOUNTIN21

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, employee compensation and consulting costs and expenses. We incurred research and development expenses of approximately $ 0.5 0.8 1.9 2.8	Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs. We incurred research and development expenses of $ 3.7
Cash and Cash Equivalents, Policy [Policy Text Block]		Cash Equivalents For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts.
Concentration Risk, Credit Risk, Policy [Policy Text Block]		Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash and cash equivalents were $ 2.3 3.6 1.9 3.1 250,000 We currently outsource all manufacturing of our clinical supplies to single source manufactures. We also have a single source supplier for the active ingredient in our prodrug compounds, including mipsagargin. A change in these suppliers could cause a delay in manufacturing and/or clinical trials, which would adversely affect our Company.
Goodwill and Intangible Assets, Policy [Policy Text Block]		Intangible Assets Intangible assets consist of licensed technology, patents, and patent applications (see Note 5). The assets associated with licensed technology are recorded at cost and are being amortized on the straight line basis over their estimated useful lives of twelve to seventeen years.
Property, Plant and Equipment, Policy [Policy Text Block]		Office Equipment Office equipment is stated at cost less accumulated depreciation. Depreciation is calculated on the straight line basis over the estimated useful lives of the assets of three to five years. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to expense. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its office equipment for impairment. Depreciation expense was approximately $ 7,000 6,000
Earnings Per Share, Policy [Policy Text Block]	Loss per Share Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. Nine months ended September 30, 2015 2014 Shares underlying options outstanding 8,921,695 8,425,095 Shares underlying warrants outstanding 26,019,583 19,897,928 Shares underlying convertible notes outstanding 276,936 268,117 35,218,214 28,591,140	Loss per Share Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. Year Ended December 31, 2014 2013 Shares underlying options outstanding 8,685,095 6,050,623 Shares underlying warrants outstanding 19,897,928 10,216,597 Shares underlying convertible notes outstanding 270,339 261,519 28,853,362 16,528,739
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.	Fair Value of Financial Instruments Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3: Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. As of September 30, 2015, the Company has no such assets or liabilities outstanding.	Fair Value Measurements The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company previously had recorded a warrant derivative liability for warrants with anti-dilution provisions, which all the respective warrants were either exercised or expired as of December 31, 2014 and 2013.
Income Tax, Policy [Policy Text Block]		Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period. Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.	Stock-Based Compensation We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period. Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
Reclassification, Policy [Policy Text Block]		Reclassifications Certain prior year balances have been reclassified to conform to current year presentation.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2014, the FASB issued Accounting Standards Update “ASU” 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This update provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments contained in this update are effective for public and nonpublic entities for annual periods ending after December 15, 2016. We are currently assessing the impact of the adoption of ASU 2014-15, and we have not yet determined the effect of the standard on our ongoing financial reporting. In January 2015, the FASB issued ASU No. 2015-01, Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, simplifying the income statement presentation. The guidance does not change the requirement to disclose items that are unusual in nature and occur infrequently. ASU No. 2015-01 is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, although early adoption is permitted. Exclusive of a material transaction that would qualify for extraordinary item presentation in future periods, we do not expect the adoption of this standard to materially impact our financial statements. In April 2015, the Financial Accounting Standard Board issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2015, and early adoption is permitted. We do not expect the adoption of this standard to materially impact our consolidated financial statements. There are various other recently issued updates, most of which represented technical corrections to the accounting literature or application to specific industries, and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.	Recent Accounting Pronouncements In August 2014, the FASB issued Accounting Standards Update “ASU” 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This Update provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments in this Update are effective for public and nonpublic entities for annual periods ending after December 15, 2016. We are currently assessing the impact of the adoption of ASU 2014-15, and we have not yet determined the effect of the standard on our ongoing financial reporting. In June 2014, the FASB issued ASU 2014-10 Development Stage Entities (Topic 915). ASU 2014-10 removes all incremental financial reporting requirements from U.S. GAAP for development stage entities. ASU 2014-10 should be applied retrospectively and is effective for fiscal years beginning after December 15, 2014. Early application is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued or made available for issuance. We have decided to adopt ASU 2014-10 early, accordingly all of the past disclosures and presentations for development stage accounting have been eliminated.

SUMMARY OF CRITICAL ACCOUNTIN22

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of September 30, 2015 and 2014, as they would be anti-dilutive: Nine months ended September 30, 2015 2014 Shares underlying options outstanding 8,921,695 8,425,095 Shares underlying warrants outstanding 26,019,583 19,897,928 Shares underlying convertible notes outstanding 276,936 268,117 35,218,214 28,591,140	The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of December 31, 2014 and 2013, as they would be anti-dilutive: Year Ended December 31, 2014 2013 Shares underlying options outstanding 8,685,095 6,050,623 Shares underlying warrants outstanding 19,897,928 10,216,597 Shares underlying convertible notes outstanding 270,339 261,519 28,853,362 16,528,739

SUPPLEMENTAL CASH FLOW INFORM23

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	The following table contains additional information for the periods reported (in thousands): Nine months ended September 30, 2015 2014 Non-cash financial activities: Common stock options issued as payment of accrued compensation $ — $ 962 Common stock issued for consulting fees 122 —	The following table contains additional information for the periods reported (in thousands). Year Ended December 31, 2014 2013 Non-cash financial activities: Common stock options issued as payment of accrued compensation $ 962 $ 999 Common stock and warrants issued for consulting fees 735 – Derivative liability reclassified to equity upon exercise of warrants – 80

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following (in thousands): September 30, 2015 December 31, 2014 Accrued compensation and benefits $ 1,877 $ 1,108 Accrued research and development 145 163 Accrued other 180 167 Total accrued expenses $ 2,202 $ 1,438	Accrued expenses consist of the following (in thousands): December 31, 2014 2013 Accrued compensation and benefits $ 1,108 $ 1,040 Accrued research and development 163 82 Accrued other 167 128 Total accrued expenses $ 1,438 $ 1,250

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2015 $ 45 Thereafter Total minimum lease payments $ 45
Restructuring and Related Costs [Table Text Block]	As part of the agreements, the executives potentially shall be entitled to the following (in thousands): Chief Chief Terminated without cause $ 1,789 $ 969 Terminated, change of control without good reason 1,789 — Terminated for cause, death, disability and by executive without good reason 381 325

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Total stock-based compensation expense recognized for stock options issued using the straight-line method in the statement of operations for the nine months ended September 30, 2015 and 2014 was as follows: Nine months ended September 30, 2015 2014 Research and development $ 28 $ 25 General and administrative 73 249 $ 101 $ 274	The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the following line items in the accompanying consolidated statement of losses (in thousands): 2014 2013 Research and development $ 891 $ 483 General and administrative 1,164 771 Total stock-based compensation expense $ 2,055 $ 1,254
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity under the Plans: Weighted- Weighted-average Aggregate average remaining intrinsic Number of exercise contractual term value (in shares price (in years) thousands) Outstanding at December 31, 2014 8,685,095 $ 1.65 Granted 376,600 $ 0.79 Exercised — — Forfeited (140,000) $ 2.17 Outstanding at September 30, 2015 8,921,695 $ 1.60 3.3 $ — Exercisable at September 30, 2015 8,712,445 $ 1.62 3.3 $ —	The following table summarizes stock option activity under the Plans: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2012 4,674,628 $ 1.79 Granted 1,515,995 $ 2.02 Exercised – – Forfeited (140,000) $ 2.80 Outstanding at December 31, 2013 6,050,623 $ 1.82 4.0 $ 272 Granted 2,759,472 $ 1.26 Exercised – – Forfeited (125,000) $ 1.50 Outstanding at December 31, 2014 8,685,095 $ 1.65 4.0 $ 46 Exercisable at December 31, 2014 8,559,895 $ 1.66 4.0 $ 46
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the nine months ended September 30, 2015 and 2014: Nine months ended September 30, 2015 2014 Volatility 58.4 % 55.6 % Expected term (years) 3.4 3.3 Risk-free interest rate 1.0 % 0.6 % Dividend yield 0 % 0 %	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued for the years ended December 31, 2014 and 2013: Year Ended December 31, 2014 2013 Volatility 55.8 % 58.8 % Expected term (years) 3.5 3.7 Risk-free interest rate 0.7 % 0.6 % Dividend yield None None

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Share-based Compensation, Activity [Table Text Block]	Transactions involving our equity-classified warrants are summarized as follows: Weighted- Weighted-average Aggregate average remaining intrinsic Number of exercise contractual term value (in shares price (in years) thousands) Outstanding at December 31, 2014 19,897,928 $ 1.54 Granted 7,694,859 $ 0.75 Exercised (337,169) $ 0.70 Forfeited (1,236,035) $ 3.16 Outstanding at September 30, 2015 26,019,583 $ 1.24 2.3 $ — Exercisable at September 30, 2015 26,019,583 $ 1.24 2.3 $ —	Transactions involving our equity-classified and liability-classified stock warrants are summarized as follows: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2012 8,513,984 $ 2.47 Granted 4,376,228 $ 1.97 Exercised (1,325,670) $ 1.06 Forfeited (1,347,945 1.52 Outstanding at December 31, 2013 10,216,597 $ 2.56 2.9 $ 48.0 Granted 11,467,847 $ 0.95 Forfeited (1,786,516) $ 2.85 Outstanding at December 31, 2014 19,897,928 $ 1.61 1.8 $ 8.4 Exercisable at December 31, 2014 19,897,928 $ 1.61 1.8 $ 8.4
Schedule of Outstanding Warrants to Purchase Common Stock [Table Text Block]	The following table summarizes outstanding common stock purchase warrants as of September 30, 2015: Weighted- average Number of exercise shares price Expiration Issued to consultants 1,057,667 $ 1.91 December 2015 through May 2020 Issued pursuant to 2011 financings 1,936,785 $ 3.24 January 2016 through April 2016 Issued pursuant to 2012 financings 296,366 $ 3.00 December 2017 Issued pursuant to 2013 financings 4,376,228 $ 1.97 December 2017 through August 2018 Issued pursuant to 2014 financings 10,882,678 $ 0.82 December 2015 through June 2019 Issued pursuant to 2014 financings 7,469,859 $ 0.75 January 2017 through July 2020 26,019,583	The following table summarizes outstanding warrants to purchase common stock as of December 31, 2014: Number of Weighted Expiration Equity–classified warrants Issued to consultants 1,045,759 $ 2.22 May 2015 through August 2019 Issued pursuant to 2010 financings 1,022,943 $ 3.38 January 2015 through May 2015 Issued pursuant to 2011 financings 1,936,785 $ 3.24 January 2016 through April 2016 Issued pursuant to 2012 financings 296,366 $ 3.00 December 2017 Issued pursuant to 2013 financings 4,376,228 $ 1.97 December 2017 through August 2023 Issued pursuant to 2014 financings 11,219,847 $ 0.93 December 2015 through June 2019 19,897,928
Schedule Of Share Based Payment Award Warrants Valuation Assumptions [Table Text Block]	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the nine months ended September 30, 2015 and 2014: Nine months ended September 30, 2015 2014 Volatility 72.7 % 52.0 % Expected term (years) 1.7 2.0 Risk-free interest rate 0.6 % 0.5 % Dividend yield 0 % 0 %	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the equity-classified warrants issued for services for the year ended December 31, 2014: Volatility 51.1 % Expected term (years) 2.0 Risk-free interest rate 0.5 % Dividend yield None

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Significant components of deferred tax assets and liabilities are as follows (in thousands): 2014 2013 Deferred tax assets: Net operating loss carryover $ 9,466 $ 7,590 Stock-based compensation 3,372 2,888 Tax credits 443 398 Total deferred tax assets 13,281 10,876 Less: valuation allowance (13,281) (10,876) Net deferred tax assets $ – $ –
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The actual tax benefit differs from the expected tax benefit for the years ended December 31, 2014 and 2013 (computed by applying the U.S. Federal Corporate tax rate of 34 2014 2013 Statutory federal income tax rate -34.0 % -34.0 % Permanent differences 0.0 % -7.0 % Adjustment for R&D Credit 0.2 % 0.2 % Valuation allowance 33.8 % 40.8 % Effective income tax rate – % – %

MANAGEMENT'S PLANS TO CONTINU29

MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN (Details Textual) - USD ($) $ in Thousands	1 Months Ended
	Jul. 31, 2015	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Management Plan [Line Items]
Deficit accumulated during the development stage		$ (44,128)	$ (39,379)		$ (32,385)
Cash and Cash Equivalents, at Carrying Value		$ 1,240	$ 2,316	$ 3,559	$ 3,587	$ 2,345
Percentage of Cash and Cash Equivalents in Total Assets		84.00%	88.00%
Proceeds from Issuance of Common Stock and Warrants	$ 2,200

SUMMARY OF CRITICAL ACCOUNTIN30

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	35,218,214	28,591,140	28,853,362	16,528,739
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	276,936	268,117	270,339	261,519
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	26,019,583	19,897,928	19,897,928	10,216,597
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	8,921,695	8,425,095	8,685,095	6,050,623

SUMMARY OF CRITICAL ACCOUNTIN31

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary Of Critical Accounting Policies [Line Items]
Research and Development Expense, Total	$ 459,000	$ 760,000	$ 1,885,000	$ 2,788,000	$ 3,691,000	$ 3,711,000
Cash and Cash Equivalents, at Carrying Value, Total	$ 1,240,000	$ 3,559,000	$ 1,240,000	$ 3,559,000	2,316,000	3,587,000	$ 2,345,000
Depreciation					7,000	6,000
Credit Concentration Risk [Member]
Summary Of Critical Accounting Policies [Line Items]
Cash					1,900,000	3,100,000
Cash, FDIC Insured Amount					$ 250,000	$ 250,000
Maximum [Member]
Summary Of Critical Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life					17 years
Property, Plant and Equipment, Useful Life					5 years
Minimum [Member]
Summary Of Critical Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life					12 years
Property, Plant and Equipment, Useful Life					3 years

SUPPLEMENTAL CASH FLOW INFORM32

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Non-cash financial activities:
Common stock options issued as payment of accrued compensation	$ 0	$ 962	$ 962	$ 999
Common stock issued for consulting fees	$ 122	$ 0	735	0
Derivative liability reclassified to equity upon exercise of warrants			$ 0	$ 80

INTELLECTUAL PROPERTY (Details

INTELLECTUAL PROPERTY (Details Textual) - USD ($)	12 Months Ended		48 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011
Intellectual Property [Line Items]
Payments To Acquire Intangible Assets			$ 212,000
Amortization of Intangible Assets	$ 17,000	$ 17,000
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	17,000
Finite-Lived Intangible Assets, Amortization Expense, Year Two	17,000
Finite-Lived Intangible Assets, Amortization Expense, Year Three	17,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four	17,000
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 17,000

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses [Line Items]
Accrued compensation and benefits	$ 1,877	$ 1,108	$ 1,040
Accrued research and development	145	163	82
Accrued other	180	167	128
Total accrued expenses	$ 2,202	$ 1,438	$ 1,250

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 100,000	$ 100,000
Debt Instrument, Interest Rate, Effective Percentage	4.20%	4.20%
Debt Instrument, Maturity Date	Dec. 6, 2011	Dec. 6, 2011
Debt Instrument, Increase, Accrued Interest	$ 33,000	$ 30,000	$ 26,000
Debt Instrument, Convertible, Conversion Price	$ 0.50	$ 0.50
Chief Executive Officer [Member]
Debt Instrument [Line Items]
Convertible Notes Payable, Total	$ 200,000	$ 200,000

COMMITMENTS AND CONTINGENCIES36

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Dec. 31, 2013USD ($)
Future Minimum Rental Payments For Operating Leases [Line Items]
2,015	$ 45
Thereafter	0
Total minimum lease payments	$ 45

COMMITMENTS AND CONTINGENCIES37

COMMITMENTS AND CONTINGENCIES (Details 1) $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)
Chief Executive Officer [Member] | Terminated without cause [Member]
Restructuring Cost and Reserve [Line Items]
Severance Provision And Indemnification Charges	$ 1,789
Chief Executive Officer [Member] | Terminated, change of control without good reason [Member]
Restructuring Cost and Reserve [Line Items]
Severance Provision And Indemnification Charges	1,789
Chief Executive Officer [Member] | Terminated for cause, death, disability and by executive without good reason [Member]
Restructuring Cost and Reserve [Line Items]
Severance Provision And Indemnification Charges	381
Chief Operating Officer [Member] | Terminated without cause [Member]
Restructuring Cost and Reserve [Line Items]
Severance Provision And Indemnification Charges	969
Chief Operating Officer [Member] | Terminated, change of control without good reason [Member]
Restructuring Cost and Reserve [Line Items]
Severance Provision And Indemnification Charges	0
Chief Operating Officer [Member] | Terminated for cause, death, disability and by executive without good reason [Member]
Restructuring Cost and Reserve [Line Items]
Severance Provision And Indemnification Charges	$ 325

COMMITMENTS AND CONTINGENCIES38

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments And Contingencies [Line Items]
Operating Leases, Rent Expense	$ 56,000	$ 55,000
Lease Expiration Date	Oct. 14, 2015

CAPITAL STOCK AND STOCKHOLDER39

CAPITAL STOCK AND STOCKHOLDER'S EQUITY (Details Textual) - USD ($)	Jun. 03, 2014	Aug. 31, 2015	Jul. 31, 2015	Mar. 31, 2015	Oct. 31, 2014	Aug. 31, 2014	Jun. 30, 2014	May. 31, 2014	Feb. 28, 2014	Aug. 31, 2013	Mar. 31, 2015	Mar. 31, 2013	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues								4,163,961		776,204		686,420				776,204
Warrant percentage to Common Stock									8.00%
Placement Agent Fee Percentage on Gross Proceeds									8.00%
Stock Issued During Period, Shares, Issued for Services			125,000						91,334
Stock Issued During Period, Value, Issued for Services			$ 95,000						$ 127,000				$ 164,000		$ 735,000
Number of Warrants Exercised													337,169			325,670
Proceeds from Warrant Exercises											$ 300,000		$ 287,000	$ 0	$ 0	$ 405,000
Shares Issued During Period Upon Exercise of Warrants																537,722
Proceeds from Issuance of Common Stock	$ 3,000,000
Reimbursement to Placement Agent	50,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.85							$ 0.85
Shares Issued, Price Per Share													$ 0.70
Warrant Expiration Period							5 years			6 months
Business Advisory Services [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services					20,000
Stock Issued During Period, Value, Issued for Services					$ 15,000
Stock Issued During Period, Value, Share-based Compensation, Forfeited		$ 25,000
Stock Issued During Period, Shares, Share-based Compensation, Forfeited		27,288
Business And Advisory Services [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights															$ 0.36
Investor And Media Relations Services [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services						189,364
Stock Issued During Period, Value, Issued for Services						$ 169,000
Phyton Biotech [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services															424,522
Stock Issued During Period, Value, Issued for Services															$ 280,000
Investor [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues							10,409,905						7,182,556	10,409,905
Warrant percentage to Common Stock									4.00%
Placement Agent Fee Percentage on Gross Proceeds									4.00%
Consultant [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services				30,000					47,800
Stock Issued During Period, Value, Issued for Services				$ 27,000					$ 67,000
Consultant [Member] | Business Advisory Services [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued for Services						$ 20,000
Consultant [Member] | Business And Advisory Services [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services						25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.80				$ 1.15
Placement Agent [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues							326,817						287,303	326,817
Shares Issued During Period Upon Exercise of Warrants							326,817
Series A Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights															$ 1.15
Series B Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights															0.85
Series C Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights															0.85
Series D Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights															$ 1.15
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues													3,591,278		4,163,961	757,794
Stock Issued During Period, Shares, Issued for Services													127,712		798,020
Stock Issued During Period, Value, Issued for Services													$ 0		$ 0
Number of Warrants Exercised													337,169
Proceeds from Warrant Exercises													$ 287,000
Series E Warrant [Member]
Class of Stock [Line Items]
Shares Issued, Price Per Share			$ 0.70
Public Offering [Member]
Class of Stock [Line Items]
Placement Agent Fees and Expense	278,000
Other Expenses	$ 64,000
Private Placement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues			3,591,278				966,250
Shares Issued, Price Per Share			$ 0.70												$ 0.80
Series C Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period New Issues Price Per Share								$ 0.80
Equity Financing [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues										3,333,356
Shares Issued During Period Upon Exercise of Warrants										5,000,032
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 1.75
Stock Issued During Period New Issues Price Per Share										$ 1.50
Beneficially Interest Percentage										4.99%
Discretionary Increase Percentage										9.99%
Commission Percentage On Gross Proceeds										8.00%						2.00%
Non Accountable Expense To Placement Agent										$ 100,001
Payments for Commissions										$ 400,003
Warrants To Purchase Of Common Stock										266,668
Legal And Due Diligence Cost										$ 35,000
Additional Placement Agent Fees										a cash fee of 4% of gross proceeds received from the exercise of the warrants, and (ii) additional transaction fees equal to 8% of gross proceeds and 8% warrant coverage for any future investment by one of the investors in the Company for a period of 12 months following the closing of the offering.
Partial Liquidated Damages Fee Percentage										1.50%

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 101	$ 274	$ 2,055	$ 1,254
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	28	25	891	483
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 73	$ 249	$ 1,164	$ 771

STOCK OPTIONS (Details 1)

STOCK OPTIONS (Details 1) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Outstanding at beginning of period (in shares)	8,685,095	6,050,623	4,674,628
Number of shares, Granted (in shares)	376,600	2,759,472	1,515,995
Number of shares, Exercised (in shares)	0	0	0
Number of shares, Forfeited (in shares)	(140,000)	(125,000)	(140,000)
Number of shares, Outstanding at end of period (in shares)	8,921,695	8,685,095	6,050,623
Number of shares, Exercisable (in shares)	8,712,445	8,559,895
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share)	$ 1.65	$ 1.82	$ 1.79
Weighted-average exercise price, Granted (in dollars per share)	0.79	1.26	2.02
Weighted-average exercise price, Exercised (in dollars per share)	0	0	0
Weighted-average exercise price, Forfeited (in dollars per share)	2.17	1.50	2.80
Weighted-average exercise price, Outstanding at end of period (in dollars per share)	1.60	1.65	$ 1.82
Weighted-average exercise price, Exercisable (in dollars per share)	$ 1.62	$ 1.66
Weighted-average remaining contractual term, Outstanding	3 years 3 months 18 days	4 years	4 years
Weighted-average remaining contractual term, Exercisable	3 years 3 months 18 days	4 years
Aggregate intrinsic value, Outstanding (in dollars)	$ 0	$ 46	$ 272
Aggregate intrinsic value, Exercisable (in dollars)	$ 0	$ 46

STOCK OPTIONS (Details 2)

STOCK OPTIONS (Details 2) - Employee Stock Option [Member]	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	58.40%	55.60%	55.80%	58.80%
Expected term (years)	3 years 4 months 24 days	3 years 3 months 18 days	3 years 6 months	3 years 8 months 12 days
Risk-free interest rate	1.00%	0.60%	0.70%	0.60%
Dividend yield	0.00%	0.00%	0.00%	0.00%

STOCK OPTIONS (Details Textual)

STOCK OPTIONS (Details Textual) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	$ 72,000		$ 43,000	$ 100,000
Employee Service Share Based Compensation Non Vested Awards Weighted Average Period For Total Compensation Cost To Be Recognized			1 year 2 months 12 days	6 months
Share Based Compensation Arrangement Options Issued To Non Employee Directors	159,000	159,000	2,107,902	1,335,972
Share Based Compensation Arrangement Options Issued To Employees And Non Employee Directors Weighted Average Price			$ 0.48	$ 0.84
Share Based Compensation Arrangement Options Issued To Consultants	217,600	391,570	651,570	180,023
Share Based Compensation Arrangement Options Issued To Consultants Weighted Average Price			$ 0.38	$ 0.75
Share Based Compensation Arrangement Options Issued To Employee Directors		1,948,902
Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	6,000,000		6,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award			4,945,874
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			1,054,126
Plan 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	12,000,000		6,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award			4,174,221
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			2,090,779
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			not less than 20% per year
Share Based Compensation Arrangement By Share Based Payment Award Vesting Period Description			period of not more than five years
Share Based Compensation Arrangement By Share Based Payment Award Assumptions Expected Term 1			10 years

WARRANTS (Details)

WARRANTS (Details) - Warrant [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Outstanding at beginning of period (in shares)	19,897,928	10,216,597	8,513,984
Number of shares, Granted (in shares)	7,694,859	11,467,847	4,376,228
Number of shares, Exercised (in shares)	(337,169)		(1,325,670)
Number of shares, Forfeited (in shares)	(1,236,035)	(1,786,516)	(1,347,945)
Number of shares, Outstanding at ending of period (in shares)	26,019,583	19,897,928	10,216,597
Number of shares, Exercisable (in shares)	26,019,583	19,897,928
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share)	$ 1.54	$ 2.56	$ 2.47
Weighted-average exercise price, Granted (in dollars per share)	0.75	0.95	1.97
Weighted-average exercise price, Exercised (in dollars per share)	0.70		1.06
Weighted-average exercise price, Forfeited (in dollars per share)	3.16	2.85	1.52
Weighted-average exercise price, Outstanding at end of period (in dollars per share)	1.24	1.54	$ 2.56
Weighted-average exercise price, Exercisable (in dollars per share)	$ 1.24	$ 1.61
Weighted-average remaining contractual term, Outstanding	2 years 3 months 18 days	1 year 9 months 18 days	2 years 10 months 24 days
Weighted-average remaining contractual term, Exercisable	2 years 3 months 18 days	1 year 9 months 18 days
Aggregate intrinsic value, Outstanding (in dollars)	$ 0	$ 8,400	$ 48,000
Aggregate intrinsic value, Exercisable (in dollars)	$ 0	$ 8,400

WARRANTS (Details 1)

WARRANTS (Details 1) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Mar. 31, 2015	Sep. 30, 2014	Jun. 30, 2014
Equity-classified warrants [Abstract]
Weighted Average Exercise price (in dollars per share)			$ 0.85
Equity Classified Warrants [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	26,019,583	19,897,928
Weighted Average Exercise price (in dollars per share)				$ 1.15	$ 1.15
Equity Classified Warrants [Member] | Consultant [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	1,057,667	1,045,759
Weighted Average Exercise price (in dollars per share)	$ 1.91	$ 2.22
Investment Warrants Expiration Date Range Start	Dec. 31, 2015	May 31, 2015
Investment Warrants Expiration Date Range End	May 31, 2020	Aug. 31, 2019
Equity Classified Warrants [Member] | Financing 2010 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)		1,022,943
Weighted Average Exercise price (in dollars per share)		$ 3.38
Investment Warrants Expiration Date Range Start		Jan. 31, 2015
Investment Warrants Expiration Date Range End		May 31, 2015
Equity Classified Warrants [Member] | Financing 2011 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	1,936,785	1,936,785
Weighted Average Exercise price (in dollars per share)	$ 3.24	$ 3.24
Investment Warrants Expiration Date Range Start	Jan. 1, 2016	Jan. 31, 2016
Investment Warrants Expiration Date Range End	Apr. 30, 2016	Apr. 30, 2016
Equity Classified Warrants [Member] | Financing 2012 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	296,366	296,366
Weighted Average Exercise price (in dollars per share)	$ 3	$ 3
Investment Warrants Expiration Date Range Start	Dec. 31, 2017
Investment Warrants Expiration Date	Dec. 31, 2017	Dec. 31, 2017
Equity Classified Warrants [Member] | Financing 2013 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	4,376,228	4,376,228
Weighted Average Exercise price (in dollars per share)	$ 1.97	$ 1.97
Investment Warrants Expiration Date Range Start		Dec. 31, 2017
Investment Warrants Expiration Date Range End	Aug. 31, 2018	Aug. 31, 2023
Equity Classified Warrants [Member] | Financing 2014 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	10,882,678	11,219,847
Weighted Average Exercise price (in dollars per share)	$ 0.82	$ 0.93
Investment Warrants Expiration Date Range Start	Dec. 31, 2015	Dec. 31, 2015
Investment Warrants Expiration Date Range End	Jun. 30, 2019	Jun. 30, 2019
Equity Classified Warrants [Member] | Financing 2015 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	7,469,859
Weighted Average Exercise price (in dollars per share)	$ 0.75
Investment Warrants Expiration Date Range Start	Jan. 31, 2017
Investment Warrants Expiration Date Range End	Jul. 31, 2020

WARRANTS (Details 2)

WARRANTS (Details 2) - Warrant [Member]	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Volatility	72.70%	52.00%	51.10%
Expected term (years)	1 year 8 months 12 days	2 years	2 years
Risk-free interest rate	0.60%	0.50%	0.50%
Dividend yield	0.00%	0.00%

WARRANTS (Details Textual)

WARRANTS (Details Textual) - USD ($)	1 Months Ended			2 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Jun. 30, 2014	May. 31, 2014	Aug. 31, 2013	Mar. 31, 2015	Mar. 31, 2013	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Warrants And Derivative Warrant Liability [Line Items]
Warrants Exercised						337,169			325,670
Warrants Exercised on Cashless Basis									1,000,000
Shares Issued During Period Upon Exercise of Warrants									537,722
Stock Issued During Period, Shares, New Issues		4,163,961	776,204		686,420				776,204
Derivative, Gain on Derivative									$ 1,100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.85
Proceeds from Warrant Exercises				$ 300,000		$ 287,000	$ 0	$ 0	$ 405,000
Common Stock Purchase Warrants Issued Shares			3,600,024						3,600,024
Share Based Compensation Expense Recognized For Warrants Issued To Consultants						$ 67,000	$ 90,000
Series B and C Warrants [Member]
Warrants And Derivative Warrant Liability [Line Items]
Warrants Expiration Date						Dec. 31, 2016
Business And Advisory Services [Member]
Warrants And Derivative Warrant Liability [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period								248,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.36
Private Offering [Member]
Warrants And Derivative Warrant Liability [Line Items]
Stock Issued During Period, Shares, New Issues	483,125
August 2013 Offering [Member]
Warrants And Derivative Warrant Liability [Line Items]
Stock Issued During Period, Shares, New Issues									686,420
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.75						$ 1.75
Consultants [Member]
Warrants And Derivative Warrant Liability [Line Items]
Stock Issued During Period, Shares, New Issues						7,469,859
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period						225,000	248,000	248,000
Allocated Share-based Compensation Expense								$ 89,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.65		$ 0.36
Warrants Weighted Average Fair Value						0.30	0.36
Placement Agent [Member]
Warrants And Derivative Warrant Liability [Line Items]
Shares Issued During Period Upon Exercise of Warrants	326,817
Stock Issued During Period, Shares, New Issues	326,817					287,303	326,817
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			18,410						18,410
Common Stock Purchase Warrants Issued Shares			266,668						266,668
Investor [Member]
Warrants And Derivative Warrant Liability [Line Items]
Stock Issued During Period, Shares, New Issues	10,409,905					7,182,556	10,409,905
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			71,374						71,374
Common Stock Purchase Warrants Issued Shares			3,333,356						3,333,356
Maximum [Member] | Business And Advisory Services [Member]
Warrants And Derivative Warrant Liability [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 3				$ 3
Minimum [Member] | Business And Advisory Services [Member]
Warrants And Derivative Warrant Liability [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.15
Equity Classified Warrants [Member]
Warrants And Derivative Warrant Liability [Line Items]
Shares Issued During Period Upon Exercise of Warrants	10,736,722						10,736,722
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.15						$ 1.15
Equity Classified Warrants [Member] | Maximum [Member]
Warrants And Derivative Warrant Liability [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	1.15					0.80	1.15
Equity Classified Warrants [Member] | Minimum [Member]
Warrants And Derivative Warrant Liability [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.85					$ 0.70	0.85
Liability Classified Warrants [Member]
Warrants And Derivative Warrant Liability [Line Items]
Warrants Exercised									242,000
Derivative Liability									$ 80,000
Series B Warrants [Member]
Warrants And Derivative Warrant Liability [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.70
Warrants Amended During The Period							3,826,792
Series C Warrants [Member]
Warrants And Derivative Warrant Liability [Line Items]
Warrants Amended During The Period							4,163,961

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryover	$ 9,466	$ 7,590
Stock-based compensation	3,372	2,888
Tax credits	443	398
Total deferred tax assets	13,281	10,876
Less: valuation allowance	(13,281)	(10,876)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Effective Income Tax Rate Reconciliation [Line Items]
Statutory federal income tax rate	(34.00%)	(34.00%)
Permanent differences	0.00%	(7.00%)
Adjustment for R&D Credit	0.20%	0.20%
Valuation allowance	33.80%	40.80%
Effective income tax rate	0.00%	0.00%

INCOME TAXES (Details Textual)

INCOME TAXES (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 27,800
Operating Loss Carryforward Expiration Dates	which will expire at various dates beginning in 2015 through 2025
Deferred Tax Assets, Tax Credit Carryforwards, Total	$ 443	$ 398
Deferred Tax Assets Tax Credit Carryforwards Expiration Dates	which will expire from 2028 through 2035
Operating Loss Carryforwards Valuation Allowance Percentage	100.00%
Valuation Allowance, Deferred Tax Asset, Change in Amount	$ 2,400	$ 1,800
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	(34.00%)	(34.00%)

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

2 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Nov. 30, 2015

Oct. 31, 2015

Jul. 31, 2015

Mar. 31, 2015

May. 31, 2014

Feb. 28, 2014

Aug. 31, 2013

Mar. 31, 2015

Mar. 31, 2013

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Dec. 31, 2013

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Issued for Services

125,000

91,334

Stock Issued During Period, Value, Issued for Services

$ 95

$ 127

$ 164

$ 735

Warrants Exercised

337,169

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.85

$ 0.85

Proceeds from Warrant Exercises

$ 300

$ 287

$ 0

$ 0

$ 405

Stock Issued During Period, Shares, New Issues

4,163,961

776,204

686,420

776,204

Consultants [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Issued for Services

30,000

Stock Issued During Period, Value, Issued for Services

$ 27

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.65

$ 0.36

Stock Issued During Period, Shares, New Issues

7,469,859

Subsequent Event [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.35

Stock Issued During Period, Shares, New Issues

75,000

Common Stock, Conversion Basis

262,500

Fair Value Assumptions, Weighted Average Expected Dividend

$ 0.15

Subsequent Event [Member] | Chief Executive Officer [Member] | Maximum [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.50

Subsequent Event [Member] | Chief Executive Officer [Member] | Minimum [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.40